Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

Re: Knock-on effects of today’s approval

There could be a halo effect to chronic HCV segment though as prescribers will get more used to prescribing Mavyret if their go-to now is GILD's products…

…if some insurers contract only w GILD they will now have to offer Mavyret and some Mavyret Rx for chronic patients would sneak through w coverage.

I would submit that these “knock-on” effects will likely be more consequential than you (and other investors) seem to think. From a medical standpoint, there is no longer a valid reason for a physician to prescribe GILD’s Epclusa to any patient—acute or chronic. (GILD’s sales of Harvoni and Vosevi are already de minimis.)